What was the overall market valuation for the Spain chorea market in 2024?

The overall market valuation was $18.0 Million in 2024. Read More

What is the projected market valuation for the Spain chorea market by 2035?

The projected market valuation for 2035 is $35.4 Million. Read More

What is the expected CAGR for the Spain chorea market during the forecast period 2025 - 2035?

The expected CAGR for the Spain chorea market during the forecast period 2025 - 2035 is 6.34%. Read More

What were the segment valuations for Huntington's disease in the Spain chorea market?

The segment valuations for Huntington's disease ranged from $8.0 Million to $15.0 Million. Read More

How does the treatment segment perform in the Spain chorea market?

The treatment segment, which includes medical and surgical care, had valuations ranging from $10.8 Million to $20.5 Million for medical care and $7.2 Million to $14.9 Million for surgical care. Read More

What distribution channels are utilized in the Spain chorea market?

Distribution channels include hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others, with valuations ranging from $1.1 Million to $8.5 Million. Read More

What symptoms are associated with chorea in the Spain market?

Symptoms associated with chorea include involuntary muscle movements, Milkmaid's grip, speech problems, and seizures, with valuations ranging from $3.0 Million to $12.0 Million. Read More

What are the end-users in the Spain chorea market?

End-users include clinics, hospitals, ambulatory surgical centers, and others, with valuations ranging from $2.7 Million to $14.0 Million. Read More

What does the future hold for the Spain chorea market?

The Spain chorea market is expected to grow significantly, reaching a valuation of $35.4 Million by 2035. Read More

Spain Chorea Market

Q: Which companies are key players in the Spain chorea market?

Key players in the market include Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Novartis AG, AbbVie Inc, Roche Holding AG, Eli Lilly and Company, Pfizer Inc, and AstraZeneca PLC. Read More

ID: MRFR/MED/51948-HCR

200 Pages

Vikita Thakur

Last Updated: February 06, 2026

Spain Chorea Market Research Report: Size, Share, Trend Analysis By Distribution Channel (hospitals, clinics, diagnostic centers, drug stores, pharmacies, others), By Symptoms (involuntary muscle movements, milkmaid's grip, speech problems, seizures), By End Users (clinics, hospitals, ambulatory surgical centers, others), By Product Type (Medication, Surgery therapy) and By Treatment (Medical care, Surgical care) - Growth Outlook & Industry Forecast 2025 To 2035

Spain Chorea Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.34%

2024 Market Size$ 18 Million

2025 Market Size$ 19.14 Million

2035 Market Size$ 35.4 Million

Key Players

Teva Pharmaceutical Industries Ltd

Bristol-Myers Squibb Company

Novartis AG

AbbVie Inc

Roche Holding AG

Eli Lilly and Company

Trends

Rising Awareness and Education
Advancements in Treatment Options
Integration of Technology in Care

Opportunities

Increasing Prevalence of Chorea
Government Initiatives and Funding
Advancements in Diagnostic Technologies

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Million)
  1. 4.1.1 Huntington's disease
  2. 4.1.2 Rheumatic (Sydenham's Chorea)
  3. 4.1.3 Drug-induced Chorea
2. 4.2 Pharmaceutical, BY Treatment (USD Million)
  1. 4.2.1 Medical care
  2. 4.2.2 Surgical care
3. 4.3 Pharmaceutical, BY Distribution Channel (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Clinics
  3. 4.3.3 Diagnostic centers
  4. 4.3.4 Drug stores
  5. 4.3.5 Pharmacies
  6. 4.3.6 Others
4. 4.4 Pharmaceutical, BY Symptoms (USD Million)
  1. 4.4.1 Involuntary muscle movements
  2. 4.4.2 Milkmaid's grip
  3. 4.4.3 Speech problems
  4. 4.4.4 Seizures
5. 4.5 Pharmaceutical, BY End-Users (USD Million)
  1. 4.5.1 Clinics
  2. 4.5.2 Hospitals
  3. 4.5.3 Ambulatory surgical centers
  4. 4.5.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis AG (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AbbVie Inc (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Roche Holding AG (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Eli Lilly and Company (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer Inc (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca PLC (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SPAIN MARKET ANALYSIS BY TYPE
3. 6.3 SPAIN MARKET ANALYSIS BY TREATMENT
4. 6.4 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 SPAIN MARKET ANALYSIS BY SYMPTOMS
6. 6.6 SPAIN MARKET ANALYSIS BY END-USERS
7. 6.7 KEY BUYING CRITERIA OF PHARMACEUTICAL
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF PHARMACEUTICAL
10. 6.10 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
12. 6.12 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
14. 6.14 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
15. 6.15 PHARMACEUTICAL, BY TREATMENT, 2024 (% SHARE)
16. 6.16 PHARMACEUTICAL, BY TREATMENT, 2024 TO 2035 (USD Million)
17. 6.17 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
18. 6.18 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
19. 6.19 PHARMACEUTICAL, BY SYMPTOMS, 2024 (% SHARE)
20. 6.20 PHARMACEUTICAL, BY SYMPTOMS, 2024 TO 2035 (USD Million)
21. 6.21 PHARMACEUTICAL, BY END-USERS, 2024 (% SHARE)
22. 6.22 PHARMACEUTICAL, BY END-USERS, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  4. 7.2.4 BY SYMPTOMS, 2025-2035 (USD Million)
  5. 7.2.5 BY END-USERS, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Spain Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Million, 2025-2035)

Huntington's disease
Rheumatic (Sydenham's Chorea)
Drug-induced Chorea

Pharmaceutical By Treatment (USD Million, 2025-2035)

Medical care
Surgical care

Pharmaceutical By Distribution Channel (USD Million, 2025-2035)

Hospitals
Clinics
Diagnostic centers
Drug stores
Pharmacies
Others

Pharmaceutical By Symptoms (USD Million, 2025-2035)

Involuntary muscle movements
Milkmaid's grip
Speech problems
Seizures

Pharmaceutical By End-Users (USD Million, 2025-2035)

Clinics
Hospitals
Ambulatory surgical centers
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”